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Background: An integral component of cancer biology is the understanding of molecular properties uniquely
distinguishing one cancer type from another. One class of such properties is histone post-translational modifications
(PTMs). Many histone PTMs are linked to the same diverse nuclear functions implicated in cancer development,
including transcriptional activation and epigenetic regulation, which are often indirectly assayed with standard
genomic technologies. Thus, there is a need for a comprehensive and quantitative profiling of cancer lines focused
on their chromatin modification states.
Results: To complement genomic expression profiles of cancer lines, we report the proteomic classification of 24
different lines, the majority of which are cancer cells, by quantifying the abundances of a large panel of single and
combinatorial histone H3 and H4 PTMs, and histone variants. Concurrent to the proteomic analysis, we performed
transcriptomic analysis on histone modifying enzyme abundances as a proxy for quantifying their activity levels.
While the transcriptomic and proteomic results were generally consistent in terms of predicting histone PTM
abundance from enzyme abundances, several PTMs were regulated independently of the modifying enzyme
expression. In addition, combinatorial PTMs containing H3K27 methylation were especially enriched in breast cell
lines. Knockdown of the predominant H3K27 methyltransferase, enhancer of zeste 2 (EZH2), in a mouse mammary
xenograft model significantly reduced tumor burden in these animals and demonstrated the predictive utility of
proteomic techniques.
Conclusions: Our proteomic and genomic characterizations of the histone modification states provide a resource
for future investigations of the epigenetic and non-epigenetic determinants for classifying and analyzing cancer
cells.Background
The search for the molecular properties that define can-
cer has provided important insights into the general can-
cerous state, as exemplified by the characterizations of
commonly mutated tumor suppressors [1]. Yet cancer is
not a single disease. Thus, it is not sufficient to only ex-
plore what broadly distinguishes the cancerous state
from the otherwise healthy state. It is essential to iden-
tify in addition the molecular properties that distinguish* Correspondence: bgarci@mail.med.upenn.edu
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reproduction in any medium, provided the ora given class of cancer cells from another. By understand-
ing both the general and specific properties defining can-
cer, one could design a comprehensive classification of
cancer cells rooted in their underlying molecular biology
and provide a resource useful for diagnosis and treatment.
Many of the properties that characterize cancer phe-
notypes operate at the genetic level, namely transcrip-
tional states and gene mutations. Genomic approaches
that collate gene expression patterns and catalog DNA
sequence information have served as a vital platform for
the profiling of a variety of cancer cells [2]. Absent from
most genomic-based classifications of cancer is epigen-
etic information, which is a grasp of the physical in vivo
state of genes. In eukaryotic cells, DNA typically exists
in a complex with histones known as chromatin. Chro-
matin can be generalized as an array of tandem coretd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of histones H2A, H2B, H3 and H4 coiling approximately
147 bp of DNA. The consequences of DNA existing in a
complex with histones are enormous. First, electrostatic
interactions between every 10 bp of DNA and the his-
tone octamer occlude various non-histone proteins from
binding those nucleotides. Second, the stability of the
nucleosome results in the need for ATP-dependent
chromatin remodelers for the positioning and alteration
in nucleosome structure. Because of these associations
between histones and DNA, it is clear that many nuclear
events, such as transcription, DNA damage repair and
replication, are impacted by the nucleosome. It is also
clear that these events broadly contribute to cancerous
development when mis-regulated, for instance, the fail-
ure to detect or repair double stranded DNA breaks.
Thus, an understanding of the cancerous state requires
an understanding of the chromatin state.
Many correlations between DNA-dependent events
and histones also occur at the level of histone post-
translational modifications (PTMs), namely lysine acetyl-
ation (ac), mono- (me1), di- (me2), and trimethylation
(me3). Most histone PTMs do not alter nucleosome
structure, rather the majority of PTMs are thought to re-
cruit non-histone proteins via specialized PTM binding
domains, such as the bromo, chromo and PHD domains.
The binding of these non-histone proteins to chromatin
can mediate many of the aforementioned events in a para-
digm known as the histone code hypothesis [3]. For in-
stance, trimethylated lysine 27 of histone H3 (H3K27me3)
is recognized by Polycomb group (PcG) proteins, which
maintain epigenetic silencing. Establishing this para-
digm is the enzymatic regulation of histone modifica-
tion states, such as histone acetyltransferases (HATs)
and methyltransferases (HMTs), which acetylate and
methylate histones respectively, and histone deacetylases
(HDACs) and demethylases (HDMs), which convert the
acetylated and methylated states, respectively, to the un-
modified state. For example, H3K27me3 is formed by the
EZH2 methyltransferase [4].
Between histone-modifying enzyme activities that
regulate histone PTM states and histone-binding pro-
teins that effect DNA-dependent processes, cancer de-
velopment has been linked to histone modifications at
various levels [5]. One example linking cancer with a
histone PTM-binding protein includes associations be-
tween bromodomain-containing BRD3 and BRD4 pro-
teins, which recognizes histones H4 acetylated at K5, K8
and K12 [6], and PAFc and SEC elongation factors in
MLL fusion leukemias [7], as well as translational fu-
sions between BRD4 and NUT proteins in certain squa-
mous carcinomas [8,9]. An example linking cancer with
a histone PTM modifying enzyme protein would be the
commonly observed mutations in EZH2 HMT in certainlymphomas and myelodysplastic syndromes that reduce
the catalytic activity to trimethylate H3K27 [10,11].
What these examples emphasize is that first, despite the
pervasive nature of histone PTMs, specific cancer phe-
notypes arise from alterations in the chromatin PTM
landscape and, second, there may potentially be many
other histone modifications of equal or greater import-
ance in cancer biology.
Given the relevance of histone PTMs to cancer, here-
tofore understood primarily using low-throughput and
often inferential approaches, there is a need for a com-
prehensive profiling of cancer cells concentrated specif-
ically on their chromatin modification states. Here we
applied mass spectrometry-based proteomic techniques
to quantify global abundances of histone PTMs from
24 commonly used cell lines, the majority of which
are of cancerous lineages. Additionally, we applied
microarray-based genomic techniques to monitor tran-
script levels of various histone-modifying enzymes. The
proteomic and transcriptomic analyses were generally
consistent in classifying which lines were similar, based
on their chromatin PTM patterns and chromatin modi-
fying enzyme levels, respectively. Among our results,
H3K27 methylation was highly increased in breast can-
cer cells. Moreover, depletion of EZH2 led to decreased
tumor formation in a mouse xenograft model, consist-
ent with the known role of EZH2 in the pathogenesis of
other cancers. In summary, this study constitutes an
“atlas” of histone PTMs across the reported lines, and
using this atlas, one may potentially attain a novel
molecular classification of cancer cells based on their
chromatin modification landscape. We believe this
dataset will motivate future studies in the cancer chroma-
tin field.
Results
A chromatin atlas of cancer lines quantifying transcript
levels of chromatin-modifying enzymes
For our chromatin-centric atlas, we examined 24 cell
lines from a diverse variety of tissue origins, including
cervix, prostate, lung and breast tissues (Table 1). The
majority of these lines are cancer cells, and the
remaining non-cancer lines include 293, HFF, HaCAT
and hESC cells. To explore whether different cell
lines would possess different chromatin profiles, we
harvested RNA from all the lines and performed gene
expression analysis using a custom microarray with
multiple probes to 224 human HATs, HDACs, HMTs
and HDMs (Figure 1).
Our hypothesis is that differences in the chromatin
state can potentially give rise to the distinguishing char-
acteristics of cancer cell lines. Indeed, cell lines that ori-
ginate from a common tissue type generally cluster
together (Figure 1). The two breast lines in our study,
Table 1 Tissue culture cell lines used in this study
Cell line Media Comment
1. 293 DMEM Embryonic kidney
2. A549 DMEM Adenocarcinomic alveolar basal epithelial
3. C33a DMEM Cervical carcinoma
4. DUT145 DMEM Prostate cancer
5. H1229 RPMI Lung carcinoma
6. HaCAT RPMI Immortalized, non-tumorigenic keratinocyte
7. HCT116 McCoy 5A Colorectal carcinoma
8. HeLa Joklik Cervical carcinoma
9. hESC2 DMEM Human embryonic stem cells
10. HFF DMEM Human foreskin fibroblasts
11. HL60 IMM Promyelocytic leukemia cells
13. Huh7.0 DMEM Hepatocarcinoma
14. Huh7.5 DMEM Hepatocarcinoma (RIG-I-deficient)
14. MCF7 DMEM Breast carcinoma
15. MDaMB231 L15 Breast carcinoma
16. Mdm13 DMEM Monocyte-derived macrophages
17. NB4 RPMI Acute promyelocytic cell line
18. PANC1 DMEM Pancreatic carcinoma, epithelial-like
19. PC3 DMEM Prostate cancer
20. SAOS McCoy 5A Epithelial-like osteosarcoma cell line
21. SW480 L15 Colon adenocarcinoma
22. U2OS DMEM Osteosarcoma
23. U251 DMEM Glioblastoma
24. U937 RPMI Leukemic monocyte lymphoma
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profiles across the histone modifying enzymes (Wilcoxon
sign rank, zval = −0.9207, P = 0.3572). While it may be
expected that two lines from different tissue types have
significantly different expression profiles, for instance, be-
tween MDA-MB231 and the leukemia HL60 line
(Wilcoxon sign rank, zval = −4.2728, P = 1.9305 × 10-5),
some lines from different tissue types have similar expres-
sion profiles. For instance, similar profiles were observed
between the HEK293 line and the U2OS cell line
(Wilcoxon sign rank, zval = −1.7466, P = 0.0807) to a mod-
est extent and between the cervical HeLa line and the PC3
prostate line (Wilcoxon sign rank, zval = −1.5303, P =
0.1259). What these results suggest is that the expression
levels of chromatin modifying enzymes alone are insuffi-
cient for distinguishing chromatin modification patterns be-
tween cancer cell lines, and that other factors may regulate
the activity of these enzymes, such as post-translational
modifications of the chromatin modifying enzymes, them-
selves likely influence the chromatin state [12]. Moreover,
these results also suggest that cancers of distinct origins
may have similar transcriptomic profiles, which should be
helpful when considering treatment options.Quantification of histone PTM abundances for a
complementary proteomic atlas
The 24 cell lines exhibited a diverse range of gene expres-
sion patterns for the various histone modifying enzymes.
Although gene expression analysis revealed both expected
and unexpected correlations across the lines, a critical
limitation of such analyses is the inability to extrapolate
enzyme activity from enzyme transcript abundance. It is
the activity of the chromatin modifying enzymes that is
most informative for designing an accurate classification
of cell lines based on their chromatin states. Thus, to com-
plement our transcriptomic analysis, our strategy to
extrapolate enzyme activity was to determine the abun-
dances of the enzyme substrates and enzyme products,
namely the steady state histone PTM levels.
In order to determine the relative abundances of his-
tone modifications for each line, we utilized our Bottom
Up MS protocol, which has also been adapted by mul-
tiple laboratories [13-15]. Here, we generated ArgC-like
fragments from acid-extracted histones and analyzed
the peptides on a hybrid Orbitrap-linear ion trap quad-
rupole mass spectrometer (ThermoFisher Scientific,
Carlsbad, CA, USA) (Figure 2). With this approach, we
reproducibly obtained greater than 90% sequence cover-
age for histones H3 and H4 and were able to quantify
37 unique histone modification patterns on histone H3
and 19 patterns on histone H4 across every cell line
(Additional file 1). We normalized all detected PTMs or
modified forms of a common peptide backbone to each
other. For instance, we would normalize the measured
abundances of all the observable modified forms of
the 9 to 17 histone H3 peptide (KSTGGKAPR), which
spans lysine 9 and lysine 14, against each other. The
normalization would occur independently of all ob-
served modified forms of another histone peptide, such
as the 18 to 26 peptide (KQLATKAAR). Because of our
normalization, our PTM values for a given peptide
backbone are not necessarily independent of each other.
Thus, for n modified forms of a given peptide, there are
n – 1 degrees of freedom. Because we quantified five
different histone H3.1/H3.2 peptide backbones: namely
the 3 to 8 peptide TKQTAR, the 9 to 17 peptide
KSTGGKAPR, the 18 to 26 peptide KQLATKAAR, the
27 to 40 peptide KSAPATGGVKKPHR, and the 73 to
83 peptide EIAQDFKTDLR, we have n – 5 degrees of
freedom along the histone H3 PTM axis. Here we have
supplied the normalized values not only in terms of fold
enrichment, but also relative abundance, thus one can
gauge the significance of the change based on the mag-
nitude of the PTM abundance. Additionally, lower
abundance marks require greater fold change to be
deemed significant and, conversely, higher abundance
marks require lower fold change to be deemed
significant.
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Figure 1 Gene expression analysis of histone modifying enzymes across cell lines. Hierarchical clustering of the 24 cell lines along the
horizontal axis was performed based on transcript abundances of HATs, HDACs, HMTs and HDMs along the vertical axis, where an orthogonal
clustering was similarly performed. The insert magnifies two clusters containing the two transcript variants of EZH2 HMT (EZH2.1 and EZH2.2).
Data are shown as log2 expression relative to the reference RNA library.
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levels of chromatin modifications
We report the modification levels on histone H3 (Figure 3)
and histone H4 (Figure 4) for each of the 24 cell lines
across the average relative abundance of all the lines. For
example, we determined the enrichment of the relative
abundance of H3K27me3K36un for MCF7 against the
average relative abundance of H3K27me3K36un across
the 24 lines. The actual and average relative abundances
for each line are also provided (Additional file 1). Analo-
gous to the transcriptomic analysis, cell lines of similar tis-
sue origin have similar chromatin modification profiles.
For instance, enrichment of a given PTM in the breast line
MCF7 is generally accompanied with similar enrichment
of the same PTM in the other breast line MDA-MB231
(Figure 3). In particular, the differences in PTM relative
abundance between the Huh7.0 and Huh7.5 were com-
parable to the differences between MCF7 and MDA-
MB231 (Wilcoxon sign rank, z =−0.0830, P= 0.9339) andbetween A549 and H1229 (Wilcoxon sign rank, z = −0.3093,
P= 0.7571). In contrast, the differences in PTM abun-
dances between PANC1 and NB4 was significantly
greater than the differences between Huh7.0 and Huh7.5
(Wilcoxon sign rank, z = −4.5334, P = 5.8034 × 10-6), im-
plying that PANC1 and NB4 have different chromatin
modification profiles. Yet there were exceptions to the
generality that lines of different tissue origins will have dif-
ferent histone PTM patterns. For instance, the differences
between SAOS and U251 were comparable to the differ-
ences between MCF7 and MDA-MB231 (Wilcoxon sign
rank, z = −0.2640, P = 0.7918) and Huh7.0 and Huh7.5
(Wilcoxon sign rank, z = −0.5959, P = 0.5512), implying a
similar chromatin modification profile of the SAOS and
U251 lines despite originating from different tissues.
Applying our analytic software, we successfully quanti-
fied the 9 to 17 H3 peptides (KSTGGKAPR) containing
serine 10 phosphorylation that otherwise would be diffi-
cult to quantify manually due to their low abundance. In
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Figure 2 Proteomic strategy for histone PTM quantification. Each of the 24 lines was similarly processed to yield the core and linker
histones. Histones were derivatized with propionic anhydride to prevent trypsin digestion at the unmodified and monomethylated lysines and,
consequently, peptides of uniform length are produced that span the same modified residue (in this example, lysines 9 and 14 of histone H3).
Relative quantification is achieved by peak integration of the extracted ion chromatograms of each charge state (the +2 charge state is shown)
for each peptide (each colored row, with m/z shown). Note that H3K9acK14un and H3K9unK14ac co-elute in this experiment, thereby requiring
tandem MS sequencing to resolve both peptides for separate quantification.
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currence of H3S10 phosphorylation, with the notable ex-
ceptions of Panc1, Huh7.0 and Huh7.5 that contain 4.4,
3.7 and 4.3% relative abundance of phosphorylated
peptides, respectively (Additional file 2). Since the cell
lines were not synchronized across the cell cycle, we
hypothesize that the levels of H3S10 phosphorylation
proportionately reflect the percentage of cells in an asyn-
chronous population that were in M phase at the time
of harvest. Furthermore, when we compared the modifi-
cation states of H3K9 and H3K14 depending on the modi-
fication state of H3S10, we observed that the H3K9 and
H3K14 modification patterns differed based on the phos-
phorylation state of H3S10. In particular, H3S10 phos-
phorylation generally co-occurred with H3K9me3K14un,
even when this modification is not particularly abundant
for a given line (Additional file 2). It is possible that thistrend reflects the methyl-phospho switch model [16],
which proposes that a key function of H3S10 phosphoryl-
ation is to block HP1 from binding to H3K9me2 or
H3K9me3. Thus, H3S10ph would be expected to co-occur
more often with H3K9me2 and H3K9me3 (that is,
H3K9me2S10ph and H3K9me3S10ph) than with H3K9un
and H3K9me1, which we observed.
Our histone H4 characterization focused on lysines 5,
8, 12 and 16 acetylation and lysine 20 mono-, di- and tri-
methylation (Figure 4). We observed that various cell
lines, namely C33a, hESC2, HCT116 and U2OS,
contained elevated levels of histone H4 acetylation, such
as the tetra-acetylated H4K5acK8acK12acK16ac form
and H4K5unK8unK12acK16ac. Enrichment for specific
acetylated patterns may have interesting implications
for Brd2, Brd3 and Brd4 recruitment, as discussed later.
In contrast, another set of lines, namely the MCF7,
Figure 3 Proteomic analysis of histone H3 PTMs across cell lines. Hierarchical clustering of the 24 lines was performed based on abundances
of histone H3 PTMs (shown in right vertical axis). Cell line tissue type is shown in the bottom horizontal axis. Data shown as log2 enrichment of
histone PTM levels for a given line (biological replicates of 3 to 7) based on average PTM levels across all 24 lines.
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H4 acetylation. It is interesting to recall that these same
three cell lines also were enriched in H3K27 methyla-
tion and depleted in H3K9ac, H3K18ac and H3K23ac
(Figure 3).
Finally, we briefly report our approximation of the distri-
bution of H2A variants across the 24 lines (Additional file 3).
There was little difference in abundance of macroH2A
and H2AZ among most cell lines, although the trend
suggests a greater abundance of H2A, in general, over
macroH2A. For instance, H1229 (Wilcoxon rank sum,
z = 2.6421 P = 0.0082) and hESC (Wilcoxon rank sum,
z = 2.8022, P = 0.0051) possessed significantly more H2AZ
than macroH2A. A notable exception is MDM13, which
has significantly higher levels of macroH2A relative to
H2AZ (Wilcoxon rank sum, z = −2.1651, P = 0.0304).
Integration of both genomic and proteomic chromatin
classifications of cell lines
In general, the genomic classification of the 24 lines was
consistent with the proteomic classification of the 24 lines.
Lines with similar expression profiles would generally have
similar histone PTM patterns, and conversely, lines with dis-
tinct expression profiles would generally have distinct his-
tone PTM patterns. Interestingly, the shortest-link clustersin the microarray data correlate well with the shortest-link
clusters in the histone H3 PTM data. Specifically, the clus-
ters (1) HEK293 and U2OS, (2) HFF, HeLa and PC3, and
(3) MCF7, PANC1 and MDA-MD231 from the microarray
data (Figure 1) reappear as clusters in the histone H3
PTM data (Figure 3). This consistency suggests that in
these cell lines the mRNA levels of the histone modifying
enzymes correlates well with their levels of enzymatic
activity.
What one can learn uniquely from both the
transcriptomic and proteomic experiments is to cross-
correlate the expression levels of every histone modify-
ing enzyme with the enrichment of every histone PTM
across all 24 lines (Figure 5). The aim of such an analysis
is to identify histone PTMs positively or negatively co-
regulated by a particular enzyme. Not only should such
cross-correlation procedures map particular modifications
for a given enzyme with the histone residues it is known
to modify, but also this approach should reveal novel
modification sites targeted by a given enzyme in vivo. We
further analyzed the expression profiles by bi-clustering
[17] within individual cell line-clusters in Figure 1 to ex-
tract correlative behavior across different cell lines. For in-
stance, re-clustering the expression profiles over only
HEK293 and U2OS (the shortest link cluster in Figure 1)
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Figure 4 Proteomic analysis of histone H4 PTMs across cell lines. Hierarchical clustering of the 24 lines was performed based on abundances
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the highest expressed transcripts for these two cell lines
(Additional file 4). This finding is consistent with the ob-
served increase in H4 acetylation in the U2OS (Figure 4).
A very similar result is obtained when bi-clustering over
only HCT116 and SW480 (two colon cancer cell lines
clustered together in Figure 1), where over an eight-fold
increase in the H4 HATs CDY1 and HAT1 is observed
(Additional file 5), and notably HCT116 is found to be
enriched in H4 acetylation (Figure 4). Bi-clustering the ex-
pression profiles over the PC3, HFF and HeLa cell line-
cluster reveals significant yet consistent changes in HMTs
within these cells lines (Additional file 6). In particular,
SETD6, PRDM5 and PRDM15 are the most significantly
over-expressed (over 3.5-fold) and PRDM12, MLL2 and
SUV420H1 are the most significantly under-expressed
(over 3.5-fold) across all 224 transcripts. Several inte-
resting patterns are also observed when bi-clustering the
expression profiles within the breast cancer-rich cluster (that
is, clustering only within the MCF7, PANC1, MDA-MB231
cell lines). Within these cell lines, a number of HMTs are
found to be consistently and significantly up-regulated
(Additional file 7). Namely, SUV420H1 (H4K20me), MLL2
(H3K4me), WHSC1 (H4K20me, H3K36me2), PRDM16
(H3K9me1), MECOM (H3K9me1), EZH2 (H3K27me2/3)and NSD1 (H3K36me) are all observed to exhibit higher
expression levels in the MCF7, PANC1 and MDA-
MB231 cell lines. The later pair of HKMTs, EZH2 and
NSD1, are particularly interesting as these cell lines also
exhibit the greatest increase in the hypermethylated
states of H3K27K36 (that is, H3K27me2K36me2, H3K
27me3K36me2, H3K27me2K36me1 and H3K27me3
K36me1 are the most abundant in these cell lines in
Figure 3). This correlative behavior between EZH2 and
NSD1 potentially suggests a direct or indirect functional
relationship between the two methyltransferases. Con-
versely, within the same cell lines there is a substantial
decrease in the HATs GTF3C4 (H3K14ac), MYST1
(H4K16ac) and CDY1 (H4ac), and this is consistent with
the observed decrease in H4 acetylation in the MCF7 and
MDA-MB231 breast cancer cell lines (Figure 4).
As highlighted in the bi-clustering analysis, one of the
more striking observations is that the two breast cell lines
in our collection, namely MCF7 and MDA-MB231, are
equally well characterized by both histone PTMs and the
expression level of the associated enzymes. In particular,
histone marks that were relatively enriched in the two cell
lines, such as H3K27me3K36me1 and H3K9me3K14un,
were also positively correlated with EZH2 expression.
Interestingly, EZH2 is also positively correlated with
Figure 5 Cross-correlation between the genomic and proteomic data. (A) Example of cross-correlation analysis between the gene
expression of a given enzyme (in this example, EZH2.2 variant) to the histone PTM log2 abundance (in this example, H3K9me3K14un) across all 24
lines (diamond). (B) Hierarchical clustering of Pearson correlation coefficients for each enzyme and histone H3 PTM cross-correlation analysis. For
instance, a positive correlation would indicate that increased enzyme transcript level is associated with increased PTM level. (C) Comparison
between enrichment of histone H3 PTMs for MCF7 and MdaMB231 (same data as found in Figure 3) and the correlation between those same H3
PTMs with EZH2 (EZH2.1 and EZH2.2) and MYST1 expression. Note, for instance, the enrichment of a given PTM (for instance, K27me3K36me2) in
the two lines is generally accompanied by a positive correlation of EZH2, and a negative correlation of MYST1, for that PTM.
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flect binding of polycomb repressive complex PRC1
(which does not contain EZH2 HMT) with H3K27me3
and H3K9me3, as previously documented. It has been
suggested that SUV39H1, an H3K9 methyltransferase,
plays a role in targeting the PCR1 complex to
H3K27me3 [18]. A more recent study analyzing the
function of EZH2 in breast and prostate cancer lines
has reported that the recruitment of EZH2 and Suz12
(both PRC2 subunits) to the promoter region of the
tumor-suppressor gene RKIP is accompanied by H3K27
and H3K9 trimethylation [19]. These two studies sup-
port our observed correlation between the methylation
levels on H3K9 and H3K27, particularly within the con-
text of breast and prostate cancer.As a reference, nearly the opposite correlations were ob-
served for MYST1, a HAT reported to acetylate H4K16.
MYST1 is negatively correlated with the aforementioned
marks yet positively correlated with H3K27acK36un and
H3K9acK14un. Indeed, this correlation makes sense from
what is currently known regarding the relationship be-
tween histone PTMs and active gene transcription, as
H4K16ac is implicated in transcriptional elongation [20],
and H3K27ac and H3K9ac are marks that associate with
active regulatory regions [21]. Taken together, our data
point to the possibility that mammary cancer cells share a
chromatin state characterized by elevated H3K27me3
levels and EZH2 expression. This suggested to us that
EZH2 would be a particularly attractive candidate to in-
vestigate with respect to these two breast cancer cell lines.
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mouse xenograft model
One of the most salient results from the proteomic atlas
of chromatin modifications is enrichment of H3K27me3
in the MCF7 and MDA-MB231 breast lines. The func-
tional roles of H3K27me3 and EZH2 in cancer progres-
sion are incompletely understood, as EZH2 has been
proposed to both promote and oppose cancer formation
and progression. From our profiling of 24 different cell
lines and from the observed influence of H3K27me sta-
tus on overall clustering, we hypothesized that lines
most enriched for H3K27me3 would be especially reliant
on this modification for their tumorigenicity. To test this
hypothesis and validate our approach experimentally, we
performed in vivo mouse xenograft tumorigenesis assays.
Here, we stably knocked down EZH2 in MDA-MB231
cells and injected control or KD cells into the mammary
fat pads of nude mice. Assessing tumor burden via non-
invasive, quantitative bioluminescent imaging, we ob-
served a striking loss of tumorigenicity in EZH2-KD
compared to control cells (Figure 6). While breast tu-
mors formed by control cells grew rapidly, reflecting the
aggressive nature of MDA-MB231 cells, EZH2-KD cells
either formed modest tumors with reduced growth ratesEZ
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Figure 6 EZH2 promotes breast cancer tumorigenesis in vivo. (A) EZH
Knockdown efficiency was assessed via quantitative RT-PCR. (B) Control or
of nude mice and tumor burden was quantified over time via weekly biolu
for each mouse. (C) Images of mice injected with control or EZH2-KD cells
SD (RT-PCR) or mean + SEM (xenografts). *P <0.05; **P <0.01.or failed to initiate tumors altogether. Overall, these re-
sults confirm the role of EZH2 in promoting breast cancer
tumorigenesis. More specifically, the magnitude of the ob-
served phenotype suggests that cell lines, such as MDA-
MB231, which harbors strongly elevated H3K27me3
levels, absolutely require high EZH2 activity for their abil-
ity to initiate and sustain malignancies.
Discussion
In this report, we provide a proteomic atlas of cancer lines
based on histone modification patterns, and a companion
genomic atlas of the same lines based on expression of
histone modifying enzymes. The primary advantages of
microarray procedures, in the context of this and similar
experiments, are minimal requirement for sample cell
amount and unsurpassed high-throughput quantification
of enzyme transcripts. The primary advantage of MS pro-
cedures is the ability to extrapolate the catalytic activity of
those enzymes by quantifying at the protein level the
abundances of the histone modifications themselves that
are the products and substrates for the enzymes. Although
not as sensitive as antibody-based characterization of his-
tone modifications, MS procedures offer a highly quantita-
tive, unambiguous and generally unbiased identification of0.1 
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EZH2-KD MDA-MB-231 cells were xenografted into mammary fat pads
minescent imagine (BLI). BLI signals are normalized to the Day 1 signal
are displayed (24 days post-injection). Data are shown as the mean +
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trolled for otherwise [22,23]. Other studies comparing
cancer types have similarly taken advantage of proteomic
approaches to characterize chromatin modification pat-
terns [24-26].
Our findings are generally consistent with other re-
ports that interrogated specific PTMs in certain cancers
(Table 2). For instance, various cancers, including HL60,
HCT116 and primary non-tissue culture cancers, have
been reported to have low levels of H4K16 acetylation
and H4K20me3 with respect to normal tissue [26]. Al-
though our analysis does not provide an immediate
comparison to normal tissue, we observed a general de-
pletion of H4K20me3, although notably not in H4K16
acetylation in both HL60 and HCT116 (Figure 4). As an-
other example, non-small cell lung cancers have been
reported to have low levels of H3K9ac and H4K16ac
[27]. Likewise in this study, one of our lung lines H1229
had reduced levels of H4K16ac independent of the
acetylation states of H4K5, K8 or K12, and reduced
levels of both H3K9acK14un and H3K9acK14ac. Yet,
there is a considerable level of inconsistency among
reports on histone modification levels, for instance,
whether low levels of H3K18ac are linked to negative
[28] or positive [29] prognosis. Much of the variability
could be due to heterogeneity of cancer cells from pa-
tients or differences in methods [30].
Our results are in slight contradiction with what was
observed in an immunohistochemistry study of the glo-
bal Ezh2 and H3K27me3 levels in breast cancer tumors
and cell lines [39], where Mda-MB231 (claudin-low sub-
type, ER-negative) was reported to have moderate ex-
pression of both EZH2 and H3K27me3, but MCF-7
(luminal subtype, ER-positive) was reported to have lowTable 2 Comparison between several observed histone PTM l
2012)
Histone modification Observation in this study
H3K4me3 Elevated in HCT116 colon line
H3K9me3 Reduced in NB4 and HL60 leukemia lines
H3K9me3 and
H3K9me3K14ac
Elevated in MDA-MB231 and MCF7 breast
lines
H3K18acK23un Reduced in 293 kidney and H1229 lung
lines
H3K27me3 Elevated in SAOS bone line
H3K27me3 Elevated in MDA-MB231 and MCF7 breast
lines
H3K36me1 and H3K36me2 Elevated in HL60 leukemia line
H4K16ac Reduced in MDA-MB231 and MCF7 breast
lines
H4K20me2 Reduced in PC3 prostate line
H4K20me3 Reduced in H1229 lung lineexpression of both EZH2 and H3K27me3. The differences
between our results and this study could potentially be
due to differences in the methodology used. Nonetheless,
our findings support the observed overexpression of Ezh2
in breast and prostate cancer [19], as DUT145, a prostatic
adenocarcinoma, was observed to exhibit significant
overexpression of Ezh2.2 (Figure 1) and belongs to the
cluster of tissues with elevated H3K27me3 levels (Figure 3).
Our ability to specify combinatorial modifications using
mass spectrometry provides a dimension of the data that
is nearly intractable from previous reports yet is an im-
portant consideration especially for the design of pharma-
cological inhibitors. Various inhibitors targeting histone
PTM binding proteins have been reported to have thera-
peutic effect towards specific cancers, for instance, the
JQ1 molecule inhibiting Brd4 binding to histone H4 [9].
Another example illustrating the relevance of combinator-
ial histone modifications is the estrogen receptor co-
activator TRIM24, which is overexpressed in breast cancer
and associates with the specific combinatorial pattern
H3K4unK23ac [40]. The methods utilized in this report
could be of considerable importance in designing new
small molecules to compete in vivo with specific histone
modification patterns and in assaying how inhibition of a
specific histone PTM binding or modifying protein would
impact other histone modification abundances on a gen-
omic scale.
Recently, there have been several fatty acyl PTMs dis-
covered on histones, including lysine crotonylation, and
other marks, such as lysine succinylation or malonylation
[13,41]. These types of modifications have been observed
by our mass spectrometry methodology, but they are ex-
tremely low level. We estimate that these marks, such as
crotonylation, are found in most cell types as low as 0.01%evels in this study and other studies (Chervona and Costa
Observation in other studies
Elevated SMYD3 HMT levels in colorectal carcinomas [31]
Reduced in promoter regions of acute myeloid leukemia patients [32]
Elevated in circulating nucleosomes of breast cancer patients [33]
Reduced in poor prognosis kidney and lung cancer patients [34]
Elevated EZH2 HMT expression in osteosarcomas [35]
Elevated EZH2 HMT expression in breast cancer [19]
Elevated recruitment of NSD1 HMT translocation in acute myeloid
leukemias [36]
Reduced in patient breast tumors [28]
Reduced in metastatic and castration-resistant prostate cancer [37]
Reduced in lung carcinoma progression [38]
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first describing these marks on histones have used either
extensive fractionation methods or pan-lysine antibodies
to first enrich for these species before mass spectrometry
detection. As they are low level, we find these marks very
difficult to robustly quantify from run to run, and have
omitted them from the current studies.
A complementary experiment and limitation in the
current work is to map where in the genome each spe-
cific histone PTM is localized for each line via ChIP-seq
and to cross-reference those genes with interesting his-
tone modification patterns to their transcriptional states.
Additionally, future investigations should apply the
methods presented in this paper to cancer cells not uti-
lized in tissue culture, but rather collected from patients
or harvested across cancer development from primary to
metastatic tumors. An interesting application would be
in the further subclassification of tumors from the same
lineage. Recent studies have shown the utility of gene ex-
pression data alone in defining new molecular subtypes
in breast cancer tumors [42]. Finally, it is important to
emphasize that the chromatin modification landscape is
but one facet underlying the complex heterogeneity of
cancer. As cancer is not a single disease, it is unlikely for
cancer to be explained using a single theoretical frame-
work. An accurate classification must consider other as-
pects, such as metabolism and global DNA methylation
patterns. For example, decreased levels in certain
microRNAs, such as miR101 and miR214, result in the
overexpression of EZH2 in cancer [43,44], and thus fac-
tors governing mRNA stability and translation should
also be measured.
Conclusion
In this report, we applied comprehensive transcriptomic
and proteomic analyses with an emphasis on chromatin
modification patterns to classify 24 commonly used cell
lines, the majority of which are cancerous. Our results
support the hypothesis that chromatin states, as defined
by the expression levels of both histone PTMs and the
associated enzymes, can serve as a basis for the
characterization of different cancer types. By systematic-
ally and unambiguously quantifying the major histone
H3 and H4 modifications, one can determine which spe-
cific histone modification exhibits the most interesting
trends, whether in terms of relative enrichment or in
terms of co-variation across similar lines. Bi-clustering
analysis showed an overall correlation between the abun-
dance of many histone PTMs and the expression of rele-
vant enzymes, illustrating the complimentary nature of
proteomic and transcriptomic data. The techniques and
results of this report should be readily extended to non-
tissue culture and clinical contexts. Finally, while we
recognize that not all molecular processes underlyingcancer are necessarily related to chromatin-related ef-
fects, we believe that the heterogeneity of the histone
code itself in terms of its chemical structures and associ-
ated functions should offer a uniquely informative vant-
age into cancer biology.Methods
Cell culture
The 24 cell lines used in this study are described in
Table 1. All lines were cultured at 37°C in 5% CO2, with
media supplemented with 1% penicillin/streptomycin,
1% glutamax and 10% fetal bovine serum. For
harvesting, suspension cells were centrifuged at 200 g at
room temperature, washed with 1× PBS, and flash fro-
zen in liquid nitrogen for long-term storage at −80°C.
Adherent cells were incubated with 10× trypsin + EDTA
for ≤5 minutes when the digestion was quenched with
serum-containing media, washed with 1× phosphate
buffered saline, and flash frozen using liquid nitrogen
for long-term storage at −80°C.
Histone protein extraction and preparation for MS
analysis
All tissue culture lines were similarly processed for his-
tone extraction [45], and the resulting histones were
processed for mass spectrometric analysis as described
previously [6].MS analysis/data analysis
Histone peptides were loaded via autosampler onto a
fused silica capillary for reversed phase high performance
liquid chromatography as described previously [6], and
electrosprayed into a hybrid linear quadrupole ion trap-
orbitrap (ThermoFisher Scientific, Carlsbad, CA, USA ) as
previously described. For each line, at least three replicates
were performed. Mass spectrometric files for the lines can
be accessed (Additional file 8) on the TRANCHE database
(https://proteomecommons.org/tranche/). Statistical ana-
lyses were performed using MATLAB (R2012a). The LC-
MS/MS data sets were analyzed using software that has
previously been described elsewhere [17,46]. Briefly, an
optimization-based model considers the MS isotopic dis-
tribution, MS/MS fragment ions and relative peptide
hydrophobicity relationships to simultaneously identify
and quantify (based on integrated peak areas) all modified
forms of the same histone peptide. All charge states for
modified peptides were included in the analysis, and the
abundance of isobaric co-eluting modified forms were
deconvoluted based upon tandem MS data as previously
described [46]. All reported identifications were validated
by manual inspection of the LC-MS/MS data.
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Agilent’s eArray (Agilent Technologies, Inc., Cedar Creek,
TX, USA) was employed to design oligo probes and as-
semble a 22 K-feature microarray. A customized set of 224
histone modifying genes (HAT, HDAC, HMT and HDM)
and 551 house-keeping genes were selected to supplement
a background consisting of the Agilent Human 1A gene
set (Additional file 9). Four different probes were selected
for each of the customized gene sets using vendor-
supplied probe design processes and associated algo-
rithms. A full list of the probes and features are available
for download (Additional file 9).
mRNA extraction and preparation for microarray analysis
Total RNA was isolated from all cell pellets by the RNeasy
RNA isolation kit (Qiagen Sciences, Germantown, MD,
USA, ). Equal amounts of RNA isolated from two dupli-
cate wells were combined before the complimentary RNA
(cRNA) amplification. The cRNA was then amplified
using the Agilent low RNA input linear amplification kit
(Agilent Technologies). The quantity and quality of cRNA
were evaluated by capillary electrophoresis using an
Agilent Technologies 2100 Bioanalyzer. Probe labeling
and microarray hybridizations were performed as de-
scribed in the Agilent 60-mer oligo microarray processing
protocol (Agilent Technologies). Cy3-labeled probes de-
rived from each of the 24 cell lines were co-hybridized
against Cy5-labeled probes derived from a common refer-
ence RNA sample on the in-house designed oligonucleo-
tide array described above. The common reference RNA
consisted of a pooling of RNA isolated from all 24 cell
lines; thus ensuring that the common reference probes
were produced in the same fashion as the other probes,
apart from the incorporation of different fluorescent dyes.
Slides were scanned with an Agilent microarray scanner
and image analysis performed using Agilent Feature
Extractor Software. GeneSpring (Agilent Technologies,
Inc., Santa Clara, CA, USA) v.9.0 was used to extract
mRNA expression data for a total of 4,893 human genes,
including the custom gene set; these mRNA expression
data were used for correlation and functional analyses
downstream.
Tumor xenograft
All animal work was performed in accordance with the
guidelines of the Institutional Animal Care and Use
Committee of Princeton University under approved pro-
tocols. For tumor formation assays, MDA-MB231 cells
were harvested from tissue culture and resuspended at a
concentration of 1 × 107 cells/ml in PBS. An incision
was made in the abdomen of female athymic Ncr-nu/nu
mice and 1 × 105 cells (10 μl) were injected into the #4
mammary fat pad of each mouse. Noninvasive biolumin-
escent imaging (BLI) was performed weekly using anIVIS 200 Imagine System (Caliper Life Sciences, Alameda,
CA USA) to quantify tumor burden over time. BLI data
analysis was performed with Living Image Software
(Xenogen, Alameda, CA USA) by measuring photon flux
in the region of interest. Data were normalized to the sig-
nal obtained immediately after injection (Day 1).
Reverse transcription and quantitative PCR
Total RNA was isolated using the RNeasy kit (Qiagen Sci-
ences) and reverse-transcribed with the Superscript III kit
(Invitrogen Life Technologies Co., Carlsbad, CA USA) fol-
lowing the manufacturer’s instructions. Quantitative PCR
was performed in triplicate using the SYBR Green PCR
Master Mix (Applied Biosystems, Warrington, UK) with
the ABI Prism 7900HT thermocycler (Applied Biosystems).
Raw EZH2 expression levels were normalized to GAPDH
expression levels. The following primers were used for
qPCR: human EZH2 forward (5′-GTGGAGCCGCTGA
CCATTGGG-3′) and reverse (5′-CCTGCCACGTCAGAT
GGTGCC-3′), and human GAPDH forward (5′- GAAGG
TGAAGGTCGGAGTC-3′) and reverse (5′- GAAGATG
GTGATGGGATTTC-3′).
Additional files
Additional file 1: Relative abundance of histone H3 and H4
modified peptides across all cell lines and replicates. These
additional files are renumbered due to the shift in position of the
previous Additional files 1 and 2 in the Methods section to the end of
the manuscript.
Additional file 2: Relative abundance of H3S10 phosphorylation
across the cell lines, normalized across all the 20 H3 9 to 17
peptides.
Additional file 3: Relative abundance of canonical H2A, H2AZ,
macroH2A and H2AX quantified across all the cell lines,
approximated by normalizing the different peptides unique to each
protein directly to each other.
Additional file 4: Up- and down-regulated enzymes in the HEK293
(neuronal precursor) and U2OS (bone) cell lines.
Additional file 5: Up- and down-regulated enzymes in the HCT116
(colon) and SW480 (colon) cell lines.
Additional file 6: Up- and down-regulated enzymes in the PC3
(prostate), HFF and HeLa (cervical) cell lines.
Additional file 7: Up- and down-regulated enzymes in the MCF7
(breast), PANC1 (pancreatic) and MDa-MB231 (breast) cell lines.
Additional file 8: Mass spectrometric files for the 24 tissue culture
cell lines can be accessed with the four hash tags on the TRANCHE
database (https://proteomecommons.org/tranche/).
Additional file 9: List of genes probed in custom microarray and
their expression in this study, with an overrepresentation of known
human histone modifying enzymes among other housekeeping
genes for all 24 tissues culture cell lines.
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